Video
Dr. Gupta discusses avelumab first-line maintenance treatment for advanced urothelial carcinoma
Author(s):
“The key message from this abstract is that the time duration for starting avelumab [Bavencio] maintenance didn't really affect the outcomes,” says Shilpa Gupta, MD.
Video Player is loading.
In this video, Shilpa Gupta, MD, discusses key findings from the study, "Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance,” which was presented at the 2021 ASCO annual meeting. Gupta is the Director of the Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic.
Related Videos
Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
Alternative treatments and patient communication for genitourinary syndrome of menopause
Amir Patel, MD, on ureteral strictures following holmium vs TFL laser lithotripsy
Prostate cancer screening: Expert weighs in after Biden's diagnosis
Sarah Razavi, MD, discusses the physical toll of ureteroscopy on urologists
Study results affirm effectiveness of evolving prostate cancer therapies
Non–Muscle Invasive-Bladder Cancer Overview
Laura Davis, MD, on link between microplastics and bladder cancer
Related Content
